Direct P70S6K1 inhibition to replace dexamethasone in synergistic combination with MCL-1 inhibition in multiple myeloma.
Journal
Blood advances
ISSN: 2473-9537
Titre abrégé: Blood Adv
Pays: United States
ID NLM: 101698425
Informations de publication
Date de publication:
22 06 2021
22 06 2021
Historique:
received:
16
10
2020
accepted:
22
03
2021
entrez:
21
6
2021
pubmed:
22
6
2021
medline:
25
6
2021
Statut:
ppublish
Résumé
Novel combination therapies have markedly improved the lifespan of patients with multiple myeloma (MM), but drug resistance and disease relapse remain major clinical problems. Dexamethasone and other glucocorticoids are a cornerstone of conventional and new combination therapies for MM, although their use is accompanied by serious side effects. We aimed to uncover drug combinations that act in synergy and, as such, allow reduced dosing while remaining effective. Dexamethasone and the myeloid cell leukemia 1 (MCL-1) inhibitor S63845 (MCL-1i) proved the most potent combination in our lethality screen and induced apoptosis of human myeloma cell lines (HMCLs) that was 50% higher compared with an additive drug effect. Kinome analysis of dexamethasone-treated HMCLs revealed a reduction in serine/threonine peptide phosphorylation, which was predicted to result from reduced Akt activity. Biochemical techniques showed no dexamethasone-induced effects on FOXO protein or GSK3 but did show a 50% reduction in P70S6K phosphorylation, downstream of the Akt-mTORC1 axis. Replacing dexamethasone by the P70S6K1 isoform-specific inhibitor PF-4708671 (S6K1i) revealed similar and statistically significant synergistic apoptosis of HMCLs in combination with MCL-1i. Interestingly, apoptosis induced by the P70S6K1i and MCL-1i combination was more-than-additive in all 9 primary MM samples tested; this effect was observed for 6 of 9 samples with the dexamethasone and MCL-1i combination. Toxicity on stem and progenitor cell subsets remained minimal. Combined, our results show a strong rationale for combination treatments using the P70S6K inhibitor in MM. Direct and specific inhibition of P70S6K may also provide a solution for patients ineligible or insensitive to dexamethasone or other glucocorticoids.
Identifiants
pubmed: 34152396
pii: S2473-9529(21)00342-6
doi: 10.1182/bloodadvances.2020003624
pmc: PMC8270664
doi:
Substances chimiques
Myeloid Cell Leukemia Sequence 1 Protein
0
Dexamethasone
7S5I7G3JQL
Ribosomal Protein S6 Kinases, 70-kDa
EC 2.7.11.1
ribosomal protein S6 kinase, 70kD, polypeptide 1
EC 2.7.11.1
Glycogen Synthase Kinase 3
EC 2.7.11.26
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2593-2607Informations de copyright
© 2021 by The American Society of Hematology.
Références
Clin Cancer Res. 2002 Jun;8(6):1681-94
pubmed: 12060604
Biochem J. 2010 Oct 15;431(2):245-55
pubmed: 20704563
Cell Cycle. 2009 Feb 15;8(4):567-72
pubmed: 19197153
Oncoimmunology. 2015 May 27;4(11):e1023973
pubmed: 26451309
Biochem J. 2012 Jan 1;441(1):1-21
pubmed: 22168436
PLoS One. 2016 Jan 15;11(1):e0147185
pubmed: 26771549
EMBO J. 2010 Sep 1;29(17):2994-3006
pubmed: 20657550
Cell Death Dis. 2020 Jun 8;11(6):442
pubmed: 32513923
J Biol Chem. 2003 Jun 27;278(26):23861-7
pubmed: 12676946
J Clin Oncol. 2006 Jan 20;24(3):431-6
pubmed: 16365178
Ann Hematol. 2019 Jan;98(1):19-28
pubmed: 30073393
Nature. 2016 Oct 27;538(7626):477-482
pubmed: 27760111
Pharmacol Ther. 2002 Oct;96(1):23-43
pubmed: 12441176
Leukemia. 2005 Jul;19(7):1248-52
pubmed: 15902294
Mol Cell. 2006 Mar 17;21(6):749-60
pubmed: 16543145
Nat Rev Cancer. 2016 Feb;16(2):99-109
pubmed: 26822577
Curr Biol. 2000 Oct 5;10(19):1201-4
pubmed: 11050388
Mol Cell. 2006 Oct 20;24(2):185-97
pubmed: 17052453
Front Oncol. 2018 Nov 20;8:533
pubmed: 30524962
Oncogene. 2002 Feb 21;21(9):1346-58
pubmed: 11857078
Cancer Res. 2007 May 15;67(10):4564-71
pubmed: 17495324
Haematologica. 2015 Feb;100(2):263-8
pubmed: 25510242
Leuk Lymphoma. 2010 Nov;51(11):1968-2005
pubmed: 20849387
Oncoimmunology. 2018 Feb 22;7(6):e1434465
pubmed: 29872571
Biochim Biophys Acta. 2010 Feb;1803(2):311-22
pubmed: 19914305
Cancer Discov. 2018 Dec;8(12):1582-1597
pubmed: 30254093
Blood. 2010 Sep 30;116(13):2215-23
pubmed: 20644120
Leuk Lymphoma. 2018 Nov;59(11):2524-2534
pubmed: 29322846
J Hematol Oncol. 2016 Jun 30;9(1):52
pubmed: 27363832
Mol Endocrinol. 2010 Jun;24(6):1136-50
pubmed: 20371704
Eur J Cancer. 2014 Mar;50(5):867-75
pubmed: 24440085
Cell. 2017 Apr 20;169(3):381-405
pubmed: 28431241
Cancer Res. 2006 Feb 1;66(3):1500-8
pubmed: 16452206
Blood. 2015 Nov 5;126(19):2179-85
pubmed: 26324701
Cancer Res. 2010 Jan 15;70(2):440-6
pubmed: 20068163
Front Endocrinol (Lausanne). 2017 Feb 06;8:16
pubmed: 28220107
Drugs. 2018 Jan;78(1):19-37
pubmed: 29188449
Cancer J. 2019 Jan/Feb;25(1):45-53
pubmed: 30694859
J Biol Chem. 2001 Jul 6;276(27):24453-6
pubmed: 11356822
Nat Rev Mol Cell Biol. 2011 Jan;12(1):21-35
pubmed: 21157483
Drugs. 2017 Dec;77(18):2057-2062
pubmed: 29127587
Mol Oncol. 2014 May;8(3):766-80
pubmed: 24661902
Leukemia. 2016 May;30(5):1086-93
pubmed: 26707935
Adv Exp Med Biol. 2015;872:315-33
pubmed: 26216001
Eur J Cancer. 2014 Mar;50(5):876-84
pubmed: 24456794
Proc Natl Acad Sci U S A. 2001 Aug 14;98(17):9666-70
pubmed: 11493700
Nat Rev Cancer. 2020 Feb;20(2):74-88
pubmed: 31686003
Blood Adv. 2019 Dec 23;3(24):4202-4214
pubmed: 31856269
Antioxid Redox Signal. 2011 Feb 15;14(4):579-92
pubmed: 20673124
Leukemia. 2013 Feb;27(2):315-24
pubmed: 22751450
Expert Opin Investig Drugs. 2019 Nov;28(11):977-988
pubmed: 31594388
Blood Cancer J. 2020 Feb 13;10(2):17
pubmed: 32054831
Cell Death Differ. 2020 Jul;27(7):2217-2233
pubmed: 31988495
Oncogene. 2002 Feb 21;21(9):1391-400
pubmed: 11857082